PSD506

PSD506 is an investigational small molecule drug candidate that was developed by the UK-based pharmaceutical company Plethora Solutions for the treatment of overactive bladder (OAB) and urge urinary incontinence. Administered orally at a dose of 20 mg daily, PSD506 was characterized as a bladder-selective agent intended to manage symptoms of urinary urgency and frequency. It reached Phase IIa clinical development, where it was evaluated in a randomized, double-blind, placebo-controlled trial involving both treatment-naïve patients and those who had undergone a washout from previous therapies. However, the development of PSD506 was discontinued after the Phase IIa results failed to demonstrate a statistically significant improvement in efficacy compared to placebo. Detailed information regarding its specific molecular target or chemical structure remains proprietary and was not disclosed in public clinical records.